ArticleRMD open2025
Opportunistic screening for osteoporosis and vertebral fracture using CT attenuation from 18F-fluorocholine PET/CT in patients with prostate cancer.
Article in RMD open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Opportunistic Screening for Low Bone Density Using Automated Vertebral Trabecular CT Attenuation from Low-Dose CT Acquired During FDG PET/CT: A Single-Center Retrospective Study.Tomography (Ann Arbor, Mich.) · 2026Article
- Feasibility of opportunistic bone health assessment using low-dose CT trabecular attenuation andFrontiers in endocrinology · 2026Article
Corrections and comments
- Commented on by
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAndrogen deprivation therapy (ADT) for prostate cancer (PCa) induces bone loss and increases fracture risk, yet baseline bone mineral density (BMD) assessment is rarely performed. Opportunistic BMD evaluation using routine imaging could improve osteoporosis screening in this population. We aimed to assess the feasibility of using trabecular attenuation (TA) in Hounsfield units (HU) from the low-dose CT component of 18F-fluorocholine (FCh) positron emission tomography (PET)/CT for opportunistic osteoporosis and vertebral fracture screening in men with PCa, compared with stand-alone diagnostic CT.
methodsIn this retrospective single-centre study, 81 patients with PCa who underwent both FCh-PET/CT and stand-alone CT within 6 months were included. TA(HU) was measured at L1-L3 vertebral levels on both scans. ADT exposure and duration were recorded to assess their associations with TA. Primary outcomes were intraclass correlation coefficients (ICC) and Bland-Altman agreement between TA values from FCh-PET/CT and stand-alone CT. Secondary outcomes included associations between TA, ADT duration and vertebral fractures.
resultsTA values from FCh-PET/CT and stand-alone CT were comparable (ICC: 0.72, 0.70 and 0.67, for L1-L3; p<0.001). Mean FCh-PET/CT TA were 121 HU (L1), 122 HU (L2) and 118 HU (L3). Lower attenuation correlated with longer ADT duration (r=-0.43; p=0.008). Vertebral fractures were observed in 18.5% of patients and were associated with lower TA (87.8 vs 127.5 HU; p=0.01).
conclusionsFCh-PET/CT provides a feasible, readily available approach for opportunistic osteoporosis and fracture risk screening in men with PCa, supporting its integration into routine imaging workflows to promote bone health assessment and fracture prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.